Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2021
Public-market disclosures about Hyaline and revenue performance
After its IPO, Zymergen disclosed limited revenue, very large losses, difficulties manufacturing Hyaline, and customer complaints concerning manufacturing compatibility. The disclosures contradicted optimistic commercial expectations, caused a major share-price decline, and were followed by shareholder lawsuits.
2021
Failure of the initial commercial product strategy
Zymergen acknowledged that Hyaline had not succeeded with customers and that the expected foldable-display market was smaller than projected. The company subsequently abandoned production and redirected its strategy.